L
Leonard P. James
Researcher at Pfizer
Publications - 15
Citations - 2007
Leonard P. James is an academic researcher from Pfizer. The author has contributed to research in topics: Lorlatinib & Anaplastic lymphoma kinase. The author has an hindex of 11, co-authored 14 publications receiving 1556 citations.
Papers
More filters
Journal ArticleDOI
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon,Benjamin Besse,Benjamin Besse,Todd M. Bauer,Enriqueta Felip,Ross A. Soo,D. Ross Camidge,Rita Chiari,Alessandra Bearz,Chia-Chi Lin,Shirish M. Gadgeel,Gregory J. Riely,Eng Huat Tan,Takashi Seto,Leonard P. James,Jill S. Clancy,Antonello Abbattista,Jean-Francois Martini,Joseph Chen,Gerson Peltz,Holger Thurm,Sai-Hong Ignatius Ou,Alice T. Shaw +22 more
TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
Journal ArticleDOI
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T. Shaw,Enriqueta Felip,Todd M. Bauer,Benjamin Besse,Benjamin Besse,Alejandro Navarro,Sophie Postel-Vinay,Sophie Postel-Vinay,Justin F. Gainor,Melissa Lynne Johnson,Jorg Dietrich,Leonard P. James,Jill S. Clancy,Joseph Chen,Jean-Francois Martini,Antonello Abbattista,Benjamin Solomon +16 more
TL;DR: In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.
Journal ArticleDOI
Resensitization to Crizotinib by the Lorlatinib Alk Resistance Mutation L1198F.
Alice T. Shaw,Luc Friboulet,Ignaty Leshchiner,Justin F. Gainor,Bergqvist S,Alexei Brooun,Benjamin J. Burke,Ya-Li Deng,W. Liu,Leila Dardaei,Rosa L. Frias,Katherine Schultz,Jennifer A. Logan,Leonard P. James,Tod Smeal,Sergei Timofeevski,Ryohei Katayama,Anthony J. Iafrate,Long P. Le,Michele McTigue,Gad Getz,Ted William Johnson,J. A. Engelman +22 more
TL;DR: In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain, and sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation.
Journal ArticleDOI
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC).
D. Ross Camidge,Sai-Hong Ignatius Ou,Geoffrey I. Shapiro,Gregory A. Otterson,Liza C. Villaruz,Miguel A. Villalona-Calero,A. John Iafrate,Marileila Varella-Garcia,Sanja Dacic,Stephanie Cardarella,Weiqiang Zhao,L. Tye,Patricia Stephenson,Keith D. Wilner,Leonard P. James,Mark A. Socinski +15 more
TL;DR: Efficacy and safety data are presented for crizotinib in patients with advanced c-Met-amplified NSCLC within 3 categories of amplification MET/CEP7 ratio ≥1.2-<5 (Intermediate) and ≥5 (High).
Journal ArticleDOI
Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).
Benjamin Solomon,Todd M. Bauer,Enriqueta Felip,Benjamin Besse,Leonard P. James,Jill S. Clancy,Karen J. Klamerus,Jean-Francois Martini,Antonello Abbattista,Alice T. Shaw +9 more
TL;DR: A selective brain-penetrant ALK/ROS1 TKI active against most known resistance mutations in anaplastic lymphoma kinase and c-ros oncogene 1 NSCLC, identifying the MTD and recommended Ph. II dose (RP2D).